More than 10 types of cancer have shown efficacy with anti-PD-1/anti-PD-L1 monotherapy, including advanced melanoma, non-small-cell lung carcinoma (NSCLC), and renal cell carcinoma (Callahan et al., 2016; Hoos, 2016). This evidence concerns the gene CD274 and non-small cell lung carcinoma.